Aqara Upgrades Iconic Cube Controller, Adding HomeKit and Alexa Support
23.11.2022 11:00:00 EET | Business Wire | Press release
Aqara, a leading provider of smart home products, introduces its new Cube T1 Pro, which is the updated version of its iconic wireless Cube controller. Built upon the success of its predecessor, the new cube adds HomeKit and Alexa support1, so that it can be used to control a wide range of smart home devices within both ecosystems. Moreover, it adds the new Scene Mode to allow users to use not only actions but also different sides of the cube to activate smart home scenes or devices2. The Cube T1 Pro is now available on Aqara Amazon brand stores in North America (US, Canada) and Europe (France, Germany, Italy, Spain, UK), and via selective Aqara retailers worldwide.
Similar to its predecessor, the Cube T1 Pro recognizes different actions such as push, shake, rotate, flip and tap. A new Scene Mode is added, and when the mode is activated the cube also recognizes different sides, so that users can simply use each side to control various scenes and devices. Dice-like indicators are printed on the sides to help users distinguish one from the others. Moreover, thanks to this new mode the Cube T1 Pro can be used in both HomeKit and Alexa. It’s also expected to support Matter via the Aqara hubs through an OTA update, and the Hub M2 will be the first hub to receive such update.
With all these improvements, the Cube T1 Pro enables a more intuitive way to control a smart home2. For instance, users can activate the Morning Routine by flipping it to Side 1, and trigger the Home Cinema Scene by flipping it to Side 2. Additionally, it’s now possible within the Aqara Home app to control more than one sets of curtains, roller shades or lights by rotating the new cube. For example, flipping it to Side 3 and rotating the cube to adjust the open percentage of the curtains, and flipping it to Side 4 and rotating to dim the Aqara lights3. The versatility of this cube controller allows users to be creative with their smart home setups.
Based on the Zigbee 3.0 protocol which allows faster response, higher reliability, better compatibility and improved energy efficiency, the Cube T1 Pro has a battery life of up to 2 years. It also supports OTA updates, which means that new features and fixes can be added to the new cube after the its initial release.
In celebration of the launch, Aqara now offers a 10% discount for the new cube on its Amazon stores. North American customers will enjoy the offer with the promo code NACUBET1 in the US and Canada, while European customers will enjoy it using the promo code CBT1PROEU in France, Germany, Italy, Spain and the UK. Both codes can be combined with coupon, and will be valid through November 24, 2022.
For more details of the Cube T1 Pro, please visit our website.
- A Zigbee 3.0-based Aqara hub is required. The Cube T1 Pro is recognized as 6 wireless buttons in HomeKit, and as 6 motion sensors in Alexa.
- A Zigbee 3.0-based Aqara hub is required.
- The compatible Aqara lights, Curtain Driver E1 or Roller Shade Driver E1 are required.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221123005015/en/
Contact information
For Media Inquiry:
media@aqara.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom